Literature DB >> 11461715

Treatment with atypical antipsychotics: new indications and new populations.

I D Glick1, S R Murray, P Vasudevan, S R Marder, R J Hu.   

Abstract

Atypical antipsychotics have revolutionized the treatment of schizophrenia, becoming the treatment of choice for patients not only during their first episode, but also throughout their life course. Of note, as of 1999 more than 70% of prescriptions for these drugs are being prescribed for conditions other than schizophrenia, such as bipolar disorder and geriatric agitation. While there have been very few controlled trials that have established the efficacy of the atypical antipsychotics for these "off-label" uses, there have been a large number of open trials and case reports. The few controlled trials suggest that the atypical antipsychotics may be useful for affective disorders (both mania and depression), geriatric conditions such as senile dementia and aggression, as well as a variety of other disorders. Atypical agents may be particularly helpful for elderly, child, or adolescent patients who are especially susceptible to the side effects of medications and whose risk of tardive dyskinesia is high but further controlled studies are necessary.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11461715     DOI: 10.1016/s0022-3956(01)00020-6

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  20 in total

1.  Multiple psychiatric diagnoses common in privately insured children on atypical antipsychotics.

Authors:  Donna R Halloran; Jason Swindle; Steve K Takemoto; Mark A Schnitzler
Journal:  Clin Pediatr (Phila)       Date:  2010-01-28       Impact factor: 1.168

2.  GLP-1 receptor agonist liraglutide reverses long-term atypical antipsychotic treatment associated behavioral depression and metabolic abnormalities in rats.

Authors:  Ajaykumar N Sharma; Sagar S Ligade; Jay N Sharma; Praveen Shukla; Khalid M Elased; James B Lucot
Journal:  Metab Brain Dis       Date:  2014-07-15       Impact factor: 3.584

3.  Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data.

Authors:  Pravin Kamble; Hua Chen; Jeffrey T Sherer; Rajender R Aparasu
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

Review 4.  Multidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.

Authors:  Noha F Minshawi; Sarah Hurwitz; Danielle Morriss; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2015-06

Review 5.  Atypical antipsychotic-induced metabolic disturbances in the elderly.

Authors:  Melanie Dawn Guenette; Araba Chintoh; Gary Remington; Margaret Hahn
Journal:  Drugs Aging       Date:  2014-03       Impact factor: 3.923

6.  Antipsychotic use in nursing home residents admitted with hip fracture.

Authors:  Hye-Young Jung; Marissa Meucci; Mark Aaron Unruh; Vincent Mor; David Dosa
Journal:  J Am Geriatr Soc       Date:  2012-12-18       Impact factor: 5.562

7.  Phospholipid profile in the postmortem hippocampus of patients with schizophrenia and bipolar disorder: no changes in docosahexaenoic acid species.

Authors:  Kei Hamazaki; Kwang H Choi; Hee-Yong Kim
Journal:  J Psychiatr Res       Date:  2010-01-06       Impact factor: 4.791

Review 8.  Long-acting injectable antipsychotics in the elderly: guidelines for effective use.

Authors:  Prakash S Masand; Sanjay Gupta
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.

Authors:  Hua Jin; Pei-an Betty Shih; Shahrokh Golshan; Sunder Mudaliar; Robert Henry; Danielle K Glorioso; Stephan Arndt; Helena C Kraemer; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2012-11-27       Impact factor: 4.384

10.  Fall-related injuries in a nursing home setting: is polypharmacy a risk factor?

Authors:  Federico Baranzini; Marcello Diurni; Francesca Ceccon; Nicola Poloni; Sara Cazzamalli; Chiara Costantini; Cristiano Colli; Laura Greco; Camilla Callegari
Journal:  BMC Health Serv Res       Date:  2009-12-11       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.